EAM
NKTR icon

Eventide Asset Management’s Nektar Therapeutics NKTR Stock Holding History

Eventide Asset Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-443,333
Closed -$4.52M – 247
2025
Q1 		$4.52M Hold
443,333
– – 0.09% 147
2024
Q4 		$6.18M Sell
443,333
-183,334
-29% -$3.23M 0.11% 148
2024
Q3 		$12.2M Buy
626,667
+124,727
+25% +$2.38M 0.21% 110
2024
Q2 		$9.34M Buy
+501,940
New +$10.6M 0.16% 125

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Eventide Asset Management's NKTR Position: Q2 2025 in Review

Eventide Asset Management sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 443,333 shares — an estimated $4.52M sold.

Eventide Asset Management first reported a position in NKTR in Q2 2024 and held it in 4 quarters. The position peaked at $12.2M in Q3 2024. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • Eventide Asset Management reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Eventide Asset Management sold 443,333 Nektar Therapeutics shares in Q2 2025, an estimated $4.52M.
  • Eventide Asset Management first reported a position in Nektar Therapeutics in Q2 2024 and held it in 4 quarters.
  • Eventide Asset Management's Nektar Therapeutics position peaked at $12.2M in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on Eventide Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.